If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 332.00
Bid: 333.00
Ask: 335.00
Change: 19.00 (6.07%)
Spread: 2.00 (0.601%)
Open: 324.00
High: 346.00
Low: 323.00
Prev. Close: 313.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Standard form for notification of major holdings

17 May 2023 09:30

RNS Number : 7197Z
Hutchmed (China) Limited
17 May 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

HUTCHMED (China) Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Canada Pension Plan Investment Board

City and country of registered office (if applicable)

Toronto, Canada

4. Full name of shareholder(s) (if different from 3.) v

Name

N/A

City and country of registered office (if applicable)

N/A

5. Date on which the threshold was crossed or reached vi:

15 May 2023

6. Date on which issuer notified (DD/MM/YYYY):

17/05/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

Less than 3%

Position of previous notification (if

applicable)

3.17

0.00

3.17

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary Shares

KYG4672N1198

SUBTOTAL 8. A

Less than 3%

Less than 3%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information xvi

 

Place of completion

London, UK

Date of completion

16 May 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLGRGDURBBDGXR
Date   Source Headline
27th Mar 20177:00 amRNS2016 Annual Report and Notice of AGM
24th Mar 20177:00 amRNSAppointment of Director
21st Mar 201710:08 amRNSChi-Med to host R&D Briefings
20th Mar 20178:04 amRNSDirectors' Share Dealing
16th Mar 201711:25 amRNSGrant of Awards under Long Term Incentive Plan
13th Mar 20177:00 amRNSPublication of Form 20-F
13th Mar 20177:00 amRNSFinal Results
10th Mar 20178:11 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
10th Mar 20177:18 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
7th Mar 201711:49 amEQSEdison issues update on Hutchison China Meditech (HCM)
3rd Mar 20177:00 amRNSPositive Fruquintinib Pivotal Phase III Results
28th Feb 201710:20 amRNSChange of Directors
20th Feb 20177:00 amRNSStart of Phase II Savolitinib PSC trial in China
14th Feb 20177:07 amRNSInitiates Phase I of Novel FGFR Inhibitor HMPL-453
14th Feb 20177:00 amRNSSavolitinib PRCC Results Presentation at ASCO GU
6th Feb 20177:00 amRNSChi-Med to Announce 2016 Final Results
1st Feb 20177:00 amRNSChange of Directors
16th Jan 201710:48 amRNSChange of Directors
16th Jan 201710:11 amRNSChange of Directors
16th Jan 20177:30 amRNSFruquintinib Phase I/II Clinical Data at ASCO GI
16th Jan 20177:29 amRNSSulfatinib Phase II Study in 2nd Line BTC in China
16th Jan 20177:16 amRNSFruquintinib Combination Study in 1st-Line NSCLC
10th Jan 20177:00 amRNSChi-Med Initiates HMPL-523 Clinical Trials
30th Dec 20169:11 amRNSTotal Voting Rights
29th Dec 20167:40 amRNSBlocklisting Six Monthly Return
20th Dec 20167:18 amRNSDirector's Share Dealing
14th Dec 20167:14 amRNSDirector's Share Dealing
6th Dec 20167:00 amRNSHMPL-523 Pre-clinical Data Presented at ASH
30th Nov 20167:51 amRNSExercise of Share Options
30th Nov 20167:48 amRNSTotal Voting Rights
23rd Nov 20167:34 amRNSDirector's Share Dealing
23rd Nov 20167:30 amRNSChi-Med to Present Data at the 17th WCLC
23rd Nov 20167:08 amRNSChi-Med to Present Data at the at the 17th WCLC
14th Nov 20169:06 amRNSChi-Med Presents Ph I Clinical Data for HMPL-523
1st Nov 20162:57 pmRNSDirector's Share Dealing
31st Oct 20167:00 amRNSJoint Venture - US$59.5m Land Compensation Payment
12th Oct 20167:00 amRNSDirector's Share Dealing
9th Aug 20168:07 amRNSDirector's Share Dealing
2nd Aug 20168:18 amRNSChange of Non-executive Directors
2nd Aug 20167:00 amRNSChi-Med 2016 Interim Results
1st Aug 20167:21 amRNSChi-Med and AstraZeneca to Accelerate Savolitinib
5th Jul 20167:00 amRNSChi-Med to Announce 2016 HY Financial Results
29th Jun 20167:00 amRNSBlocklisting Six Monthly Return
20th Jun 20167:00 amRNSSavolitinib Global Phase II Trial Initiated
15th Jun 20168:09 amRNSAdditional Listing
31st May 20167:00 amRNSTotal Voting Rights
13th May 20167:00 amRNSEnrollment completion of Phase III fruquintinib
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20161:12 pmRNSResults of Annual General Meeting
13th Apr 20164:23 pmRNSExercise of Overallotment Option

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.